2021-12-16
On December 16, 2021, Zai Lab, an innovative global bio-pharmaceutical company, announced that its product, Nuzyra® (Omadacycline Tosilate), has been approved by NMPA as Category I new drug for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI). Hanhui Pharma has been granted exclusive promotion rights for Nuzyra® in mainland China.
2021-12-08
The Pharmaceutical Industry-Education Integration Base of Bijie Medical College & Hanhui Pharmaceutical Co., Ltd. was established on December 8. The project with first phase of three years will efficiently speed up the construction and operation of the integration system of internship and employment between the college and Hanhui. It explores and implements the pilot program of modern apprenticeship system, by which the students will receive education from both college and enterprise. This project will provide talents for the pharmaceutical industry, promote the co-education and sharing of talents between colleges and enterprises to achieve a high degree of fit between talent training, industry needs and job positions.
2021-12-03
On December 3, 2021, the National Healthcare Security Administration published the 2021 National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance. Saisimei® (Hybutimibe Tablets), the first cholesterol absorption inhibitor with independent intellectual property rights in China, has been included in the NRDL. It is indicated as adjunctive therapy to diet, either alone or with HMG-CoA reductase inhibitors (statins), for the treatment of primary (heterozygous familial or non-familial) hypercholesterolemia, reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (ApoB) levels.
2021-11-23
On November 23, 2021, the supplementary application of Hanhui Pharma for Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin®) was approved by NMPA, i.e., NMPA approved Pfizer Limited to transfer the manufacturing technology of its innovator product Piperacillin Sodium and Tazobactam Sodium for Injection to Hanhui Pharma.
2021-11-06
During the 4th China International Import Expo, Hanhui Pharma signed a strategic cooperation agreement with the Yilijk Internet medical platform on November 6. The two parties will integrate resources and jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality closed loop of out-of-hospital health management for patients with chronic diseases.
2021-10-23
On October 23, 2021, nearly 100 cardiovascular experts gathered in Guangzhou to witness the marketing of Saisimei®, the first independently developed cholesterol absorption inhibitor in China! Experts at the ceremony agreed that Saisimei® will provide more options for lipid-lowering treatment in China and will better serve Chinese patients.
2021-10-12
On October 12, 2021 annual summit of China Pharmaceutical Industry Association (CPIA) and the 7th (expanded) meeting of its ninth Board of Directors was held in Wuhan. The list of “2021 China Pharmaceutical Outstanding Enterprise and Outstanding Product Brand Cultivation Program” was announced, which is sponsored by CPIA, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association, China Association for Vaccines and Reed Sinopharm Exhibitions Co., Ltd. Hanhui Pharma won 8 awards of “Outstanding Pharmaceutical Product Brand”, and the number of awards was at record highs.
2021-12-16
On December 16, 2021, Zai Lab, an innovative global bio-pharmaceutical company, announced that its product, Nuzyra® (Omadacycline Tosilate), has been approved by NMPA as Category I new drug for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI). Hanhui Pharma has been granted exclusive promotion rights for Nuzyra® in mainland China.
2021-12-08
The Pharmaceutical Industry-Education Integration Base of Bijie Medical College & Hanhui Pharmaceutical Co., Ltd. was established on December 8. The project with first phase of three years will efficiently speed up the construction and operation of the integration system of internship and employment between the college and Hanhui. It explores and implements the pilot program of modern apprenticeship system, by which the students will receive education from both college and enterprise. This project will provide talents for the pharmaceutical industry, promote the co-education and sharing of talents between colleges and enterprises to achieve a high degree of fit between talent training, industry needs and job positions.
2021-12-03
On December 3, 2021, the National Healthcare Security Administration published the 2021 National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance. Saisimei® (Hybutimibe Tablets), the first cholesterol absorption inhibitor with independent intellectual property rights in China, has been included in the NRDL. It is indicated as adjunctive therapy to diet, either alone or with HMG-CoA reductase inhibitors (statins), for the treatment of primary (heterozygous familial or non-familial) hypercholesterolemia, reducing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (ApoB) levels.
2021-11-23
On November 23, 2021, the supplementary application of Hanhui Pharma for Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin®) was approved by NMPA, i.e., NMPA approved Pfizer Limited to transfer the manufacturing technology of its innovator product Piperacillin Sodium and Tazobactam Sodium for Injection to Hanhui Pharma.
2021-11-06
During the 4th China International Import Expo, Hanhui Pharma signed a strategic cooperation agreement with the Yilijk Internet medical platform on November 6. The two parties will integrate resources and jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality closed loop of out-of-hospital health management for patients with chronic diseases.
2021-10-23
On October 23, 2021, nearly 100 cardiovascular experts gathered in Guangzhou to witness the marketing of Saisimei®, the first independently developed cholesterol absorption inhibitor in China! Experts at the ceremony agreed that Saisimei® will provide more options for lipid-lowering treatment in China and will better serve Chinese patients.
2021-10-12
On October 12, 2021 annual summit of China Pharmaceutical Industry Association (CPIA) and the 7th (expanded) meeting of its ninth Board of Directors was held in Wuhan. The list of “2021 China Pharmaceutical Outstanding Enterprise and Outstanding Product Brand Cultivation Program” was announced, which is sponsored by CPIA, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association, China Association for Vaccines and Reed Sinopharm Exhibitions Co., Ltd. Hanhui Pharma won 8 awards of “Outstanding Pharmaceutical Product Brand”, and the number of awards was at record highs.
